Bishnu K Khand* and Ramesh R Bhonde Pages 1 - 7 ( 7 )
Pluripotent Stem Cells [PSCs] are emerging as an excellent cellular source for treatment of many degenerative diseases such as diabetes, ischemic heart failure, Alzheimer’s disease. PSC-derived pancreatic islet β-cells appear to be as a promising therapy for type 1 diabetes patients with impaired β-cell function. Several protocols have been developed to derive β-cells from PSCs. However, these protocols produce β-like cells that show low glucose stimulated insulin secretion [GSIS] function and mirror GSIS profile of functionally immature neonatal β-cells. Several studies have documented a positive correlation between the sirtuins [a family of ageing-related proteins] and the GSIS function of adult β-cells. We are of the view that GSIS function of PSC-derived β-like cells could be enhanced by improving the function of sirtuins in them. Studying the sirtuin expression and activation pattern during the β-cell development and inclusion of the sirtuin activator and inhibitor cocktail [specific to a developmental stage] in the present protocols may help us derive functionally mature, ready-to-use β-cells in-vitro making them suitable for transplantation in type 1 diabetes.
Pluripotent Stem Cells [PSCs], Pancreatic islet β-cells, Glucose stimulated insulin secretion [GSIS], Sirt1, Type 1 diabetes, Uncoupling Protein2 [UCP2]
Department of Molecular Reproduction, Development and Genetics, Indian Institute of Science, Bangalore-560012, Dr D. Y. Patil Vidyapeeth, Pimpri, Pune-411018